bosentan anhydrous has been researched along with Skin Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballmer, A; Brady, B; Clingan, PR; Hersey, P; Kefford, RF; Morganti, A | 1 |
| Ballmer, A; Beith, JM; Clozel, M; Kefford, R; Kusic, R; Millward, M; Morganti, A; Nayler, O; Segal, E; Shreeniwas, R; Trotter, JM; Van Hazel, GA; Wyld, DK | 1 |
2 trial(s) available for bosentan anhydrous and Skin Neoplasms
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bosentan; Dacarbazine; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Sulfonamides | 2010 |
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Australia; Bosentan; Endothelin Receptor Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Receptors, Endothelin; RNA, Messenger; Skin Neoplasms; Sulfonamides; Tablets; Tomography, X-Ray Computed; Treatment Outcome | 2007 |